Stille

Stille EBITDA Margin

The EBITDA Margin of Stille (STIL.ST) as of Oct 27, 2026 is 12.81 %. In the previous year, EBITDA Margin was 14.87 % — a change of -13.87% (lower).

EBITDA Margin

12.81 %

YoY

-13.87%

Last updated:

EBITDA Margin of Stille is 2025 12.81 % . EBITDA Margin of Stille was 2024 14.87 % . It decreases by -13.87% lower compared to the previous year.

The Stille EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
18.63 SEK
Jan 1, 2019
18.65 SEK
Jan 1, 2020
8.08 SEK
Jan 1, 2021
11.53 SEK
Jan 1, 2022
13.89 SEK
Jan 1, 2023
15.24 SEK
Jan 1, 2024
14.87 SEK
Jan 1, 2025
12.81 SEK
The Stille EBITDA Margin history
YEAREBITDA MarginYoY
12.81 %-13.87%
14.87 %-2.46%
15.24 %+9.72%
13.89 %+20.45%
11.53 %+42.69%
8.08 %-56.67%
18.65 %+0.13%
18.63 %+20.19%
15.50 %-8.22%
16.89 %+38.29%
12.21 %+773.51%
1.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stille Stock analysis

What does Stille do? Stille AB generates revenue by developing and selling medical equipment through two distinct business lines. The Surgery business area focuses on handcrafted, forged surgical instruments for open surgery, particularly in cardiovascular, reconstructive, and aesthetic plastic surgery. This segment produces essential tools such as scissors, forceps, artery forceps, needle holders, and clamps for medical professionals requiring precision instruments. The second revenue stream comes from the Patient Positioning area, which manufactures specialized procedure-specific tables. These devices are designed for cardiovascular surgery as well as gynecology, urology, and urodynamic examinations. By offering tailored positioning solutions for these specific medical fields, the company supports clinical procedures that require precise patient alignment. The company's operational structure includes wholly owned subsidiaries Stille Surgical Inc. and Stille Incentive AB, which support its manufacturing and distribution efforts. In 2013, the company adjusted its portfolio by selling its Sonesta business unit to ADDvise Lab Solutions publ AB, allowing it to focus on its core surgical and positioning equipment offerings. Stille is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stille stock

EBITDA Margin of Stille is 12.81 % in 2025.

EBITDA Margin of Stille changed from 14.87 % to 12.81 %, representing a -13.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Stille since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Stille with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Stille

All Key Metrics — Stille